论文部分内容阅读
目的 评估脑卒中患者的治疗结果有许多方法,文献所见至少有27种都是评测患侧上肢功能和灵巧度的,其中上肢动作研究(ARA)试验有很高的信度、效度和实用性。它主要用于对慢性卒中患者偏瘫上肢进行强制性使用治疗的效果评估,以总分57分的10％为具临床意义的最小差值(MCID)。ARA试验的有效性必须是测定的误差小于MCID(即5.7分)。本研究的目的在于验证ARA试验的评测者内(intrarater)和评测者间(interrater)的信度,评估其发现有临床意义最小差值5.7分的能力,并确定其不可靠的测试条目。
PURPOSE: There are many ways to assess the outcome of stroke patients. At least 27 of the literature reviews the function and dexterity of the affected upper limbs. The ARA test has high reliability, validity, and utility Sex. It is primarily used to assess the effect of mandatory treatment of hemiplegic upper extremities in patients with chronic stroke, with a clinically significant minimum difference (MCID) of 10% of the total score of 57 points. The effectiveness of the ARA test must be that the measured error is less than the MCID (ie 5.7 points). The aim of this study was to validate the intrarater and interrater reliability of the ARA trial and assess its ability to find a clinically significant difference of 5.7 points and to determine its unreliable test items.